Comparison
3 Methylglutaconic Aciduria Type Viib C5676893 vs 3mc Syndrome 2 C0796279
Clinical comparison between 3 Methylglutaconic Aciduria Type Viib and 3mc Syndrome 2 for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type Viib C5676893
A rare genetic metabolic condition impacting mitochondria, similar to type VIIa. It causes neurological and developmental problems that require lifelong management. Treatment involves supportive therapies tailored to individual symptoms.
3mc Syndrome 2 C0796279
A rare genetic condition similar to other 3MC types, affecting multiple systems with facial, developmental, and growth manifestations. Treatment focuses on symptom management.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type Viib C5676893
0-5
3mc Syndrome 2 C0796279
0-0
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type Viib C5676893
severe
3mc Syndrome 2 C0796279
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type Viib C5676893
Chronic
3mc Syndrome 2 C0796279
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type Viib C5676893
No
3mc Syndrome 2 C0796279
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type Viib C5676893
metabolic
3mc Syndrome 2 C0796279
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type Viib C5676893
metabolic
3mc Syndrome 2 C0796279
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-viib-C5676893 and 3mc-syndrome-2-C0796279 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type Viib C5676893 | 3mc Syndrome 2 C0796279 | Discriminating power |
|---|---|---|---|
| Core pattern | Metabolic mitochondrial disorder with neurological and developmental problems. | Congenital multisystem syndrome with facial, growth, and developmental features. | High |
| Onset | Reported onset from birth through age 5. | Congenital presentation at birth. | Moderate |
| Physical findings | No defining malformation pattern is established in the supplied data. | Facial and growth manifestations are described features. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type Viib C5676893 when
Early neurological or developmental concerns suggest mitochondrial disease.
The left condition is classified as a severe metabolic mitochondrial disorder.
Moderate
Testing raises concern for 3-methylglutaconic aciduria.
The named metabolic abnormality directs evaluation toward the left diagnosis.
Moderate
Long-term neurodevelopmental support is the main need.
The source describes chronic neurological and developmental problems.
High
Choose 3mc Syndrome 2 C0796279 when
Congenital facial, growth, and multisystem features are present.
These manifestations match the described congenital syndrome.
Moderate
No primary metabolic aciduria is confirmed.
Clinical genetics may then be more informative than metabolic testing.
Low
Supportive care is planned from birth.
The right condition is congenital and symptom-managed.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type Viib C5676893 | 3mc Syndrome 2 C0796279 | Interpretation |
|---|---|---|---|
| Urine organic acids | 3-methylglutaconic acid may be elevated; no cutoff is established here. | No defining aciduria pattern is supplied. | An abnormal result requires specialist confirmation and is not itself a diagnosis. |
| Genetic testing | May support a metabolic or mitochondrial diagnosis. | May support 3MC syndrome 2. | Variant significance must be interpreted by a genetics clinician. |
| Dysmorphology and growth assessment | No characteristic congenital pattern is established. | Facial and growth findings are important clinical clues. | Findings need correlation with genetics and the overall phenotype. |
Prognosis comparison
3 Methylglutaconic Aciduria Type Viib C5676893
- Outcome
- A severe chronic course is described, but individual outcome is not established.
- Factors
- Neurological burden, developmental needs, and response to supportive care.
3mc Syndrome 2 C0796279
- Outcome
- A moderate chronic congenital course is described; prognosis is not quantified.
- Factors
- Extent of facial, growth, developmental, and multisystem involvement.
Time frame: Lifelong
Early recognition, specialist follow-up, supportive therapies, and associated complications.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurological impairment | Neurological problems are emphasized and may be severe. Neurological severity is not established. Specific deficits and frequency are not supplied. |
| Developmental problems | Developmental problems require lifelong management. Developmental manifestations are part of the syndrome. Individual trajectories require clinician assessment. |
| Growth and multisystem involvement | Metabolic and neurological effects are the stated focus. Growth and multiple congenital systems may be affected. Organ-specific complications are not established. |
Patient education highlights
- HighConfirming the diagnosis
A test abnormality or clinical resemblance needs genetics and specialist review before diagnosis.
- HighSupportive care
Both conditions are chronic; care is individualized and symptom-focused, with no standard dose given here.
- MediumMonitoring
Report neurological, developmental, growth, feeding, or new congenital concerns promptly.